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Abstract
Neutralizing antibodies are a significant component of the host’s protective response against flavivirus infection.
Neutralization of flaviviruses occurs when individual virions are engaged by antibodies with a stoichiometry that exceeds a
required threshold. From this ‘‘multiple-hit’’ perspective, the neutralizing activity of antibodies is governed by the affinity
with which it binds its epitope and the number of times this determinant is displayed on the surface of the virion. In this
study, we investigated time-dependent changes in the fate of West Nile virus (WNV) decorated with antibody in solution.
Experiments with the well-characterized neutralizing monoclonal antibody (MAb) E16 revealed a significant increase in
neutralization activity over time that could not be explained by the kinetics of antibody binding, virion aggregation, or the
action of complement. Additional kinetic experiments using the fusion-loop specific MAb E53, which has limited
neutralizing activity because it recognizes a relatively inaccessible epitope on mature virions, identified a role of virus
‘‘breathing’’ in regulating neutralization activity. Remarkably, MAb E53 neutralized mature WNV in a time- and temperature-
dependent manner. This phenomenon was confirmed in studies with a large panel of MAbs specific for epitopes in each
domain of the WNV envelope protein, with sera from recipients of a live attenuated WNV vaccine, and in experiments with
dengue virus. Given enough time, significant inhibition of infection was observed even for antibodies with very limited, or
no neutralizing activity in standard neutralization assays. Together, our data suggests that the structural dynamics of
flaviviruses impacts antibody-mediated neutralization via exposure of otherwise inaccessible epitopes, allowing for
antibodies to dock on the virion with a stoichiometry sufficient for neutralization.
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Introduction
Flaviviruses are a group of ,70 RNA viruses that cause
morbidity and mortality on a global scale, with greater than 100
million human infections annually [1]. Viruses within this genus of
medical concern include yellow fever virus, tick-borne encephalitis
virus, Japanese encephalitis virus, dengue virus (DENV) and West
Nile virus (WNV). WNV is a mosquito-borne flavivirus maintained
innature inanenzooticcyclewith birds.WNVinfectionsofhumans
result in a spectrum of clinical symptoms depending, in part, on the
age and immune status of the individual. While most infections are
sub-clinical, symptomatic cases range from self-limiting fever to
acute flaccid paralysis and encephalitis [2]. Since its introduction
into North America in 1999, as many as three million people have
been infected by WNV [3], with ,1000 severe infections occurring
in the United States annually (www.cdc.gov). To date, there are no
WNV-specific treatments or vaccines licensed for use in humans.
Flaviviruses are small spherical virions that encapsidate an
,11 kb genomic RNA of positive-sense polarity [1]. This RNA is
translated as a single polyprotein that is processed by viral and host
cell proteases into ten functionally distinct proteins. Flaviviruses
encode three structural proteins that comprise the virus particle
and seven non-structural proteins that function to process the viral
polyprotein, replicate the viral genome, and antagonize the host’s
protective response to infection [1,4,5,6,7,8,9,10,11]. Flaviviruses
bud into the endoplasmic reticulum as immature viruses that
incorporate 60 heterotrimeric spikes of the envelope (E) and
precursor to membrane (prM) proteins [12,13]. Maturation of
virions during egress from the cell is associated with a pH-
dependent change in the arrangement and oligomeric state of the
E protein and cleavage of prM by a host cell furin-like serine
protease [14,15,16]. While prM cleavage is a required step in the
formation of an infectious virion [17], several lines of evidence
suggest that a significant fraction of infectious virions retain some
uncleaved prM [18,19,20,21,22]. The E protein is a class II fusion
protein composed of three structurally distinct domains (domains
I-III; E-DI-III) connected to the viral membrane by a helical stem
region [23]. On mature virions, 180 copies of the E protein are
arranged as anti-parallel dimers in an unusual herringbone T=3
pseudo-icosahedral array [24,25,26]. In this configuration, E
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chemical environments defined by their proximity to the two-,
three-, or five-fold symmetry axis. This arrangement adds
complexity to the antigenic surface of virus particles as antibodies
may not be able to bind all 180 E proteins due to steric constraints
on antibody binding or occlusion of the epitope itself [27,28].
Humoral immunity is a critical aspect of protection against
flavivirus infection (reviewed in [29]). Eliciting a protective antibody
response is a primary goal in the development of safe and effective
flavivirus vaccines [30]. The majority of neutralizing antibodies
against flaviviruses are directed against the E protein; neutralizing
monoclonal antibodies (MAbs) have been identified that bind to all
three Eproteindomains (reviewedin[29,31]).Whileantibodiesthat
bind the prM protein have been detected in humans, they possess
limited neutralizing activity [32,33,34,35,36].
Antibody-mediated neutralization of WNV is a ‘‘multiple-hit’’
phenomenon that occurs when virions are engaged by antibody
with a stoichiometry that exceeds a required threshold [29,37].
Our estimate of this threshold is ,30 antibody molecules per
virion [38]. Two factors principally govern the neutralizing activity
of an antibody. Antibody affinity (or avidity) controls the fraction
of accessible epitopes on the intact virion occupied at a particular
concentration of antibody. From a vaccination standpoint,
eliciting antibodies that bind viral antigens with high affinity is
desirable because they can reach the stoichiometric threshold
required for neutralization at lower concentrations. However,
high-affinity interactions do not always translate into significant
functional potency. Because of steric constraints arising from the
dense icosahedral arrangement of E proteins on the mature virion,
not all epitopes are displayed on intact virions equivalently.
Epitope accessibility is a second independent parameter that
defines the circumstances that allow for neutralization, and differs
markedly between antibodies that recognize structurally distinct
epitopes [21,28,38,39,40]. In fact, many epitopes, including those
recognized by antibodies commonly elicited in vivo, are not
displayed on the surface of the mature virion enough times to
allow for neutralization even when fully occupied [21,38,41].
An important concept of the ‘‘multiple-hit’’ model of neutrali-
zation is that infectious virions may be decorated with non-
neutralizing quantities of antibody. Evidence in support of this
includes increases in the neutralizing activity of antibodies observed
in the presence of anti-IgG secondary antibodies or complement
[37,42,43], and the phenomenon of antibody-dependent enhance-
ment (ADE) of infection [44]. Because the rate of antibody-virion
interactions is orders of magnitude faster than the rate of virus
bindingto cells,virusesarelikely engaged byantibody forsignificant
periods prior to productive interactions with target cells. Here, we
investigated the fate of virions decorated by antibody with a
stoichiometry that does not exceed the threshold required for
neutralization.Ourdata revealedtime-andtemperature-dependent
increases in neutralization of WNV that would not be predicted for
static virions bound by antibodies under steady-state conditions.
Because both viral proteins and intact virions are dynamic
[45,46,47,48], the increased neutralization can be explained by
changes in epitope accessibility occurring as virions sample different
states of a dynamic ensemble of conformations. That kinetic aspects
of neutralization were observed for every WNV- and DENV-
reactive MAb examined, as well as WNV-polyclonal immune sera,
suggests a widespread impact of the dynamic motion of virions on
epitope accessibility and antibody-mediated neutralization.
Results
Antibody modulates the infectious half-life of WNV in
solution
To investigate whether prolonged exposure of virions to ‘‘non-
neutralizing’’ quantities of antibody has functional consequences,
we performed a series of kinetic experiments with the WNV E-DIII-
lateral ridge specific MAb E16 at a concentration sufficient to
neutralize the infectivity of half the virus particles (the EC50). At this
concentration, half the virions in a population are bound by
antibody with a stoichiometry that exceeds the neutralization
threshold, whereas the other half are bound by fewer antibody
molecules. WNV reporter virus particles (RVPs) encoding a GFP
reporter gene were incubated with 10 ng/ml E16 for one hour at
room temperature to allow for steady-state binding (Figure S1).
After the room temperature incubation, RVP-antibody complexes
were shifted to 37uC for the indicated periods prior to the addition
of target Raji-DC-SIGNR cells. The infectivity of RVPs in the
presence and absence of antibody was determined by flow
cytometric analysis, and is expressed relative to the level of
infectivity observed when cells were added to viral immune
complexes immediately after the initial room temperature incuba-
tion (Figure 1a). Using this approach, we observed an antibody-
independent decrease in RVP infectivity with prolonged incubation
at 37uC (intrinsic decay), consistent with our previously published
findings [49]. Incubation in the presence of E16 resulted in a 4.7-
foldreduction inthe apparenthalf-life of WNV RVPs relative to the
intrinsic rate of decay observed in the absence of antibody (n=23;
p,0.0001) (Figure 1b). A similar 5.6-fold change in the rate with
which virions lost infectivity in the presence of E16 was observed
using fully-infectious WNV (Figure 1c). Incubation of RVPs or
virus with high concentrations of the DENV-specific MAb 3H5 did
not impact WNV infectivity, indicating a requirement for virus-
reactive antibody (Figure 1b and c). These results were not
explained by increased binding of virions to tissue-culture plastic
during prolonged incubation with antibody (p=.32, n=5; Figure
S2a), the action of complement (p=.17, n=5; Figure S2b), or
antibody-mediated aggregation (E16 Fab experiments discussed
below; Figure 2b). Additionally, the rapid reduction in RVP
infectivity in the presence of virus-specific antibody was still
Author Summary
Neutralizing antibodies are a critical aspect of protection
from flavivirus infection. The primary targets of neutraliz-
ing antibodies are the envelope (E) proteins incorporated
into virions. The neutralizing activity of antibodies is
determined by the affinity with which they interact with
the virion, and the total number of sites available for
binding. In this study, we investigate the impact of
dynamic motion of the viral E proteins on antibody-
mediated neutralization. Using panels of monoclonal
antibodies and immune sera, we demonstrate that the
dynamic motion of virions significantly impacts antibody-
mediated neutralization of West Nile and dengue viruses
by modulating epitope accessibility. Increasing the length
of the interactions between antibody and virus resulted in
increased neutralization reflecting engagement of epi-
topes that are not exposed on the surface of the virion in
its average state, but instead become accessible through
the dynamic motion of E proteins. While examples of the
impact of structural dynamics on antibody binding have
been described previously, our data suggests this phe-
nomenon plays a role in neutralization by all antibodies
that bind the array of E proteins on the virion. Our data
identifies epitope accessibility as a critical, yet dynamic,
factor that governs the neutralizing activity of anti-
flavivirus antibodies.
Kinetic Aspects of WNV Neutralization
PLoS Pathogens | www.plospathogens.org 2 June 2011 | Volume 7 | Issue 6 | e1002111Figure 1. The functional half-life of WNV decreases in the presence of virus-specific antibody. (A) WNV RVPs were incubated in the
absence or presence of sub-neutralizing concentrations (the EC50) of the MAb E16 for one hour at room temperature to allow binding to reach
equilibrium. RVP-antibody complexes were then incubated at 37uC for the indicated times. The infectivity at each point was determined following
infection of Raji-DC-SIGNR cells and monitored by flow cytometry 48 h post-infection. The data is presented normalized to levels obtained prior to
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(p=.74, n=2; Figure S2c), suggesting that the loss of infectivity
cannot be explained by physical destruction of RVPs due to
contaminating proteases.
A kinetic aspect of neutralization by the WNV-specific
MAb E16
We next evaluated the impact of kinetics on neutralization by E16
in a series of dose-response studies. WNV RVPs were incubated with
serial four-fold dilutions of E16 at room temperature for one hour,
followed by a shift to 37uC for the indicated times prior to the
addition of target cells (Figure 2a). The dose-response profile of E16
obtained when cells were added immediately after the room
temperature incubation required to achieve steady-state binding
revealed the expected relatively steep sigmoidal curve (Figure 2a;
reference curve) [38]. Dose-response curves obtained from samples
incubated for varying lengths of time at 37uC prior to the addition of
cells differed from the reference curve in several respects. First, the
percentage of cells infected in the presence of low concentrations of
antibody (the top of the sigmoidal dose-responsecurve) decreased as a
function of increased incubation at 37uC, corresponding to the
intrinsic decay of virus particles observed in the kinetic studies
Figure 2. Kinetic changes in antibody-mediated neutralization of WNV infection by the DIII-specific MAb E16. Nine serial four-fold
dilutions of MAb E16 (A) or E16 Fab fragments (B) were incubated with WNV RVPs for one hour at room temperature to allow binding to reach
equilibrium. RVP-antibody complexes were then incubated at 37uC for incremental lengths of time before infecting Raji-DC-SIGNR cells. Infectivity
was monitored by flow cytometry at 48 h post-infection. The reference curve represents RVP-antibody complexes added to target cells immediately
after the room temperature incubation. For A, dose-response curves from a representative experiment are expressed relative to the infectivity of RVPs
in the absence of antibody that were added to cells immediately after the room temperature incubation (left panel), or relative to the infectivity of
RVPs in the absence of antibody at each individual time point (right panel). For B, the E16 Fab fragment results from a representative experiment
are displayed relative to the infectivity of RVPs in the absence of antibody at each individual time point. Error bars display the standard error of
duplicate infections. Results are representative of 19 and two independent experiments for A and B, respectively.
doi:10.1371/journal.ppat.1002111.g002
incubation at 37uC (but after steady-state binding was reached) and fitted to a single-phase exponential decay to obtain the half-life. For the
representative experiment shown, dotted lines represent 95% confidence intervals and error bars represent the standard error of duplicate
measurements. The fold-reduction in the half-life of WNV RVPs (B) or infectious WNV (C) in the presence of sub-neutralizing quantities of MAb E16
(n=23 and n=2, respectively) or high concentrations of the DENV-specific MAb 3H5 (n=2), as compared to the absence of antibody, are shown. Error
bars represent the standard error.
doi:10.1371/journal.ppat.1002111.g001
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increasing the length of incubation at 37uC shifted the EC50 to lower
concentrations of antibody (Figure 2a; right panel (n=19,
p,0.0001)). Analysis of changes in infectivity over time revealed a
5.8-fold decrease in the apparent half-life at ,10 ng/ml E16 relative
to the antibody-independent intrinsic decay for RVPs alone (n=18
independent dose-response experiments, p,0.0001), similar to the
results obtained using the single antibody-concentration studies
described in Figure 1. Time-dependent changes in dose-response
curves were also observed with Fab fragments of E16 (,3.8-fold
decrease in EC50 after 24 hr incubation, n=2) (Figure 2b),
indicating the phenomenon does not reflect antibody-mediated virus
aggregation.
Kinetic aspects of the antibody dependent enhancement
(ADE) profile of MAb E16
ADEdescribesthedramaticincrease ininfectionofFcc-receptor-
expressing cells in the presence of non- or weakly-neutralizing
quantities of antibody and has been linked to severe clinical
outcomes following secondary DENV infections of humans
(reviewed in [50]). Antibody-mediated neutralization and ADE
are two phenomena related by the number of antibodies bound to
the virion [38,51], therefore kinetic changes in the neutralization
activity of an antibody should have a corresponding impact on the
ADE profile as well. To explore this, kinetic dose-response curves
were set up as described above, except using FccIIb-expressing
K652 target cells. Infection of K562 cells occurs through Fcc-
receptor-mediated uptake of antibody-virus immune complexes; in
the absence of antibody, these cells are refractory to infection due to
an inability to efficiently bind WNV. When immune complexes
were added to cells immediately following the room temperature
incubation required to achieve steady-state binding (Figure 3;
reference curve), the expected bell shaped dose-response profile was
observed. Incubation of antibody-virion complexes at 37uC prior to
the addition of cells resulted in a marked change in the shape of the
ADE profile. A reduction in the magnitude of ADE was observed
over time, consistent with a decrease in the number of infectious
virions in solution due to intrinsic decay (Figure 3; left panel).
Notably, prolonged incubation resulted in a reduction in the
concentration of E16 at which maximal ADE was observed
(Figure 3; right panel), corresponding to the reduction in the
EC50 observed above (Figure 2a; right panel).
Because the kinetic neutralization and enhancement experi-
ments presented above were designed to allow for steady-state
binding of the virion by antibody prior to incubation at 37uC
(validated in Figure S1), changes in virus infectivity over time
should not reflect continued engagement of individual virions by
increasing numbers of antibody molecules. However, an important
assumption of this model is that the number of epitopes on the
virion does not change.
Dynamic motion changes epitope accessibility in a time-
and temperature-dependent manner
To explore the role of dynamic motion of the virion in WNV
neutralization, we took advantage of the fact that the neutralizing
activity of several classes of antibodies is significantly limited by
epitope accessibility [21,39,40]. MAb E53 is a high affinity DII-
fusion loop-reactive antibody that has a limited capacity to
neutralize mature virions because its epitope is buried on the
surface of the virus particle. Even in the presence of saturating
concentrations of antibody, E53 does not bind mature virions
enough times to exceed the stoichiometric requirements for
neutralization [21]. In support, structural studies revealed that
E53 Fab fragments were only capable of binding E proteins of the
heterotrimeric spikes present on immature virions [52]. For E53 to
engage a mature virion with a stoichiometry that exceeds the
neutralization threshold, changes in the accessibility of its
otherwise cryptic epitopes would be required.
In agreement with our previous findings [21], MAb E53 failed
to significantly neutralize a homogeneous population of mature
WNV RVPs when antibody-virion complexes were added to cells
following a one hour incubation at room temperature (Figure 4a
and b, reference curves). Incubation at 37uC for increasing time
intervals prior to infection revealed a gradual increase in
antibody potency, with more than half the virions incubated at
37uC for 26 hours becoming susceptible to neutralization
(Figure 4a). Because the E53 epitope is not accessible on the
highly ordered surface of the mature virion [52], the increase in
potency requires changes in exposure of the fusion loop epitope
over time as the E proteins on the surface of the virion sample
Figure 3. Kinetic changes in antibody dependent enhancement (ADE) of WNV infection by the MAb E16. Nine serial four-fold dilutions
of MAb E16 were incubated with WNV RVPs for one hour at room temperature to allow binding to reach equilibrium. RVP-antibody complexes were
then incubated at 37uC for incremental lengths of time before infecting K562 cells. Infectivity was monitored by flow cytometry at 48 h post-
infection. The reference curve represents RVP-antibody complexes added to target cells immediately after the room temperature incubation. Dose-
response curves from a representative experiment are expressed relative to the maximum infectivity of RVPs that were added to cells immediately
after the room temperature incubation (left panel), or relative to the maximum infectivity of RVPs at each individual time point (right panel). Error
bars display the standard error of duplicate infections. Results are representative of four independent experiments.
doi:10.1371/journal.ppat.1002111.g003
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potential to stabilize the epitope in an exposed conformation that
occurs only transiently in the absence of antibody. That
significant neutralization requires considerable time at 37uC
likely reflects the relatively large number of epitopes that must
become accessible on the average virion in order to exceed the
neutralization threshold (Figure S3). If increased neutralization
by E53 reflects dynamic movement of the virion, one would
predict it would be both time- and temperature-dependent. To
test this, we performed additional experiments with longer
incubation times and a range of temperatures. Increasing the
temperature to 40uC enhanced neutralization as compared to
37uC( Figure 4b, compare green to orange curves), whereas
decreasing the temperature to 33uC reduced neutralization
capacity (Figure 4b, compare green to blue curves). Similar
results were observed for the E-DI specific MAb E121 shown
previously to bind an epitope that is poorly accessible on the
mature virion (Figure 4c)[ 2 1 , 3 9 ] .
Viral dynamics broadly impact antibody-mediated
neutralization of flaviviruses
To investigate whether kinetic effects on antibody-mediated
neutralization are a common phenomenon, we performed
additional studies using a panel of 12 WNV MAbs. In each case,
we observed time- and temperature-dependent increases in
neutralization, similar to our results with E16, E53, and E121
(Figure 5). Collectively, the 15 WNV MAbs used in the current
study bind epitopes distributed across all three domains of the E
protein and are characterized by varying degrees of functional
potency [39,53]. We next performed experiments using previously
characterized immune sera from five recipients of a phase I clinical
trial of a live attenuated WNV vaccine [21] (A. Durbin, S.
Whitehead, and colleagues, unpublished data). After a one hour
room temperature incubation to allow for steady-state binding,
virus-sera mixtures either were used to immediately infect cells
(Figure 6, reference curves) or incubated an additional 23 hours
at 37uCo r4 0 uC before infection (Figure 6, blue and orange
Figure 4. Time- and temperature-dependent increases in neutralization by antibodies that bind cryptic determinants on the
mature virion. Nine serial four-fold dilutions of the DII-fusion loop (fl)-reactive MAb E53 (A and B) or the DI-reactive MAb E121 (C) were incubated
with mature WNV RVPs for one hour at room temperature to allow binding to reach equilibrium. RVP-antibody complexes were then incubated at
37uC only (A)o ra t3 3 uC, 37uC, and 40uC( B and C) for incremental lengths of time before infecting Raji-DC-SIGNR cells. Infectivity was carried out at
37uC and monitored by flow cytometry at 48 h post-infection. The reference curve represents RVP-antibody complexes added to Raji-DC-SIGNR cells
immediately after the room temperature incubation. Dose-response curves from representative experiments are expressed relative to the infectivity
of RVPs in the absence of antibody at each individual time point. Error bars display the standard error of duplicate infections. Results are
representative of five and three independent experiments for MAb E53 and E121, respectively.
doi:10.1371/journal.ppat.1002111.g004
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antibody present in immune sera behaved in a manner similar to
MAb of defined specificity.
To extend our observations to another flavivirus, we performed
analogous studies with DENV serotype 1 (DENV-1) RVPs and a
panel of previously characterized DENV-1 E protein-reactive
MAbs [53,54]. After incubating RVPs and antibody at 37uC for
one hour to allow steady-state binding to occur, RVP-antibody
complexes were either immediately used to infect cells (Figure 7,
reference curves) or further incubated for two or seven additional
hours at 37uC and 40uC before infection (Figure 7, dotted
curves). Because it was established previously that some antibodies
do not bind DENV efficiently at low temperatures [46],
incubation at 37uC was used to establish steady-state binding
(Figure S1). As observed in our studies with WNV, time- and
temperature-dependent increases in neutralization potency were
Figure 5. Kinetic changes in neutralization occur for WNV MAbs specific for structurally distinct epitopes. Nine serial four-fold dilutions
of various WNV MAbs were incubated with mature WNV RVPs for one hour at room temperature to allow binding to reach equilibrium. RVP-antibody
complexes were then incubated at 37uCo r4 0 uC for incremental lengths of time before infecting Raji-DC-SIGNR cells. Infectivity was monitored by
flow cytometry at 48 h post-infection. The reference curve represents RVP-antibody complexes added to Raji-DC-SIGNR cells immediately after the
room temperature incubation. Dose-response curves are expressed relative to the infectivity of RVPs in the absence of antibody at each time point.
Error bars display the standard error of duplicate infections. Results are representative of two independent experiments. MAbs selected for study
were specific for epitopes on the DII-fusion loop (DII-fl) (A), the DII-central interface, DII-dimer interface, and DII-hinge interface (E48, E100, and E113,
respectively) (B), the DIII-lateral ridge (DIII-lr) (C), and epitopes within DIII that fall outside of the lateral ridge (D).
doi:10.1371/journal.ppat.1002111.g005
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necessary as compared to experiments with WNV, due to a more
rapid intrinsic decay rate of DENV as compared to WNV, which
has previously been reported [49]. This was also demonstrated in
parallel studies of WNV and DENV-1 RVPs with the cross-
reactive MAb E60; significant increases in neutralization were
observed more rapidly with DENV than WNV (Figure S4).
Altogether, these results suggest that DENV exists in a more
dynamic state than WNV.
Discussion
The existence of high-resolution structures of the E proteins of
flaviviruses, and their arrangement on the surface of the virion at
different stages of the viral lifecycle, have been a powerful tool for
studying how these viruses interact with the host (reviewed in
[6,26]). Interpretation of these structures in the context of
biological systems is complicated by the fact that they represent
the average state of what is likely a very dynamic ensemble of
conformations sampled by virions at equilibrium. The structural
dynamics of non-enveloped viruses have been studied extensively
(reviewed in [45,55]). Limited proteolysis studies of the Flock
house virus strongly suggest the capsid proteins ‘‘breathe’’,
allowing proteases access to internal structures predicted to be
inaccessible on an intact and non-dynamic virion [47]. Further-
more, drugs that prevent the dynamic movement of the
picornavirus human rhinovirus 14 have been shown to effectively
inhibit infectivity [48]. While the dynamics of enveloped viruses
have been studied less extensively, examples of temperature- and
time-dependent antibody reactivity have been described for
several viruses [46,56,57]. The DENV group-reactive neutralizing
MAb 1A1D-2 binds an epitope on the A-strand of E-DIII that is
poorly accessible on proteins proximal to each of the three
symmetry axes of the mature virion. Binding of this MAb is
temperature-dependent (does not occur at 4uC) and appears to
trap E proteins on the virion surface in a conformation distinct
from the herringbone icosahedral arrangement of the mature
virion [46].
Overall, prior studies implicating a kinetic component of
antibody-mediated neutralization have focused on either a single
MAb (DENV MAb 1A1D-2, influenza MAb Y8-10C2) or a panel
of MAbs that recognizes a similar epitope (MAbs specific for the
membrane-proximal external region (MPER) of HIV gp41), with
the implication that such antibodies were atypical in their ability to
bind buried or inaccessible epitopes [57,58,59]. In this study we
provide functional evidence identifying the widespread impact of
the dynamic movement of flaviviruses on neutralization by all
antibodies that bind the E protein; a kinetic aspect of
neutralization appears to be the rule rather than the exception.
Our data suggest that the structural dynamics of virions has the
potential to modulate the potency of all antibodies that bind E
proteins arrayed on the surface of the virion through changes in
epitope accessibility. This is illustrated most dramatically by
antibodies that bind poorly accessible determinants on the mature
virion, such as the WNV DII-fusion loop-reactive MAb E53.
Neutralization of mature WNV by E53 is restricted by the number
of times the antibody can bind the virion. E53 binds the E protein
only when associated with prM as heterotrimeric spikes that
project off the surface of the immature virus particle [21,52].
While homogeneous populations of mature WNV are not
efficiently neutralized by E53 when assayed using conventional
approaches, increasing the time the virus is incubated with
antibody resulted in a marked increase in neutralization activity
(.100-fold) (Figure 4a and b). Because the virus cannot revert to
an immature configuration once prM cleavage occurs and the
virion is released from the cell [15], this dramatic increase in
neutralization can only be explained by exposure of the DII-fusion
loop epitope through dynamic motion of viral E proteins.
Figure 6. Kinetic effects of WNV neutralization by polyclonal sera. Nine serial three-fold dilutions of five heat-inactivated polyclonal WNV
immune sera samples were incubated with mature WNV RVPs for one hour at room temperature to allow binding to reach equilibrium. RVP-antibody
complexes were then incubated at 37uCo r4 0 uC for incremental lengths of time before infecting Raji-DC-SIGNR cells. Infectivity was carried out at
37uC and monitored by flow cytometry at 48 h post-infection. The reference curve represents RVP-antibody complexes added to Raji-DC-SIGNR cells
immediately after the room temperature incubation. Dose-response curves from a representative experiment are expressed relative to the infectivity
in the absence of antibody at each individual time point. Error bars display the standard error of duplicate infections. Data is representative of two
independent experiments.
doi:10.1371/journal.ppat.1002111.g006
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polyclonal (n=5) antibody assayed in this study was enhanced by
increasing the time the virion was exposed to antibody prior to the
addition of target cells, including antibodies previously demon-
strated to be non- or weakly-neutralizing using standard assays.
This reflects the fact that as the number of accessible epitopes on
the individual virion increases as a consequence of dynamic
motion, the fraction of them that must be bound in order to
exceed the stoichiometric threshold (percent occupancy) is
reduced; neutralization can then occur at lower concentrations
of antibody. However, the magnitude of this kinetic effect was not
uniform among antibodies localizing to different epitopes. This
may reflect differences in the number of times an antibody binds
the average state of the virion relative to the threshold number of
antibodies required for neutralization, as well as the rate at which
additional epitopes are made available for binding (Figure S3). In
contrast to the cryptic nature of the DII-fusion loop epitope
recognized by E53, the potently neutralizing MAb E16 is specific
for a relatively accessible determinant displayed on the lateral
ridge of DIII [53]. Cryo-electron microscopy studies indicate this
antibody binds 120 out of 180 E proteins incorporated into mature
virions; the remaining 60 E proteins proximal to the five-fold
Figure 7. A kinetic aspect of neutralization is also observed with DENV. Nine serial four-fold dilutions of various DENV-1-reactive MAbs were
incubated with DENV-1 RVPs for one hour at 37uC to allow binding to reach equilibrium. RVP-antibody complexes were then incubated at 37uCo r
40uC for incremental lengths of time before infecting Raji-DC-SIGNR cells. Infectivity was carried out at 37uC and monitored by flow cytometry at 48 h
post-infection. The reference curve represents RVP-antibody complexes added to Raji-DC-SIGNR cells immediately after the one hour incubation at
37uC. Dose-response curves from a representative experiment are expressed relative to the infectivity in the absence of antibody at each individual
time point. Error bars display the standard error of duplicate infections. Data is representative of three (E95, E105) or two (E60, E102, E113)
independent experiments. E95, E102, E105, and E113 are DIII-reactive MAbs specific for the G-strand, BC-loop, BC/DE/FG loops, and A-strand,
respectively. E60 is a WNV-specific MAb that is cross-reactive for the DENV DII-fusion loop.
doi:10.1371/journal.ppat.1002111.g007
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among the tightly clustered DIII epitopes [27,28]. An increase in
the accessibility of these additional epitopes on the virion through
dynamic motion would translate into a modest reduction in the
occupancy requirements for neutralization by E16, in agreement
with the 4.0-fold increase in antibody potency (n=11, range 2.3–
6.8) observed in our studies after ,24 hours incubation. A similar
3.8-fold increase after ,24 hours was observed when E16 Fab
fragments were used (n=2, range 3.2–4.5).
The dynamic motion of virions has the potential to increase
antibody potency by providing access to otherwise cryptic
antibody-binding determinants. Of note, mapping studies suggest
that many epitopes on the mature virion are poorly accessible for
antibody binding [38,39,40,46]. Antibodies do not induce viral
breathing, but rather stabilize conformations of the E protein that
exist as part of the ensemble of conformations sampled by the
virion at equilibrium. The longer the virion remains exposed to
antibody, the more opportunities exist for engagement of an
otherwise inaccessible epitope, allowing for time-dependent
increases in the stoichiometry with which antibodies decorate
virions. If changes in epitope accessibility are the underlying
mechanism of the kinetic aspects of neutralization, there should be
a limit to the increase in potency observed over time. Eventually,
dynamic virion structures should expose all potential epitopes, and
these will become fixed in place by antibody binding, yielding a
neutralization profile determined by the relationship between
antibody occupancy and the stoichiometric threshold. In support
of this, increases in neutralization and changes in the ADE curves
for E16 no longer occurred when incubations longer than
24 hours were performed (Figure S5).
In addition to exposing more epitopes for antibody binding,
time-dependent changes in the antigenic surface of the virus
particle may also allow engagement of the virion with increased
affinity, via bivalent interactions among E proteins in conforma-
tions not present in the average state, as well as cooperative effects
during antibody binding. That the kinetic impact on neutralization
by E16 was observed using both intact antibodies and Fab
fragments incapable of cross-linking virions indicates that increases
in antibody potency do not reflect antibody-mediated aggregation
among virions. Importantly, all of the experiments included in our
study were performed using conditions of antibody excess, and
yielded results that were independent of the concentration of virus
in the assay. In contrast, the aggregation of antigens by antibodies
is dependent on the antibody-antigen ratio.
Our results suggest that changes in the antibody-mediated
neutralization of DENV occur more rapidly than with WNV. One
interpretation of this result is that DENV virions are more
dynamic than those of WNV, allowing more rapid access to
otherwise inaccessible determinants. In the absence of antibody,
preparations of DENV become less infectious at a faster rate than
observed with WNV, consistent with prior studies [49]. Addition-
ally, kinetic changes in neutralization with the cross-reactive MAb
E60 occur at a faster rate with DENV-1 than WNV RVPs when
compared in parallel studies (Figure S4). While we do not yet
understand, in molecular terms, why viruses lose infectivity over
time, one possibility is that the intrinsic decay of flaviviruses is a
consequence of structural dynamics. Viruses sampling multiple
conformations in dynamic equilibrium may not always return to
the average state because moving backwards may no longer be the
most energetically favorable path. Additional evidence of time-
dependent structural changes to the virus population is demon-
strated by differences in the intrinsic decay rate of WNV observed
when different cell types are used to measure infectivity. The rate
of decay of viruses was ,2.7-fold more rapid when assayed on
Raji-DC-SIGNR cells as compared to a K562 cell line expressing
the same attachment protein (n=6, p,0.0001). Thus, the
observed intrinsic decay cannot be attributed solely to the physical
destruction of the virus, and suggests the additional possibility that
not all conformations in a heterogeneous ensemble of virions are
equally infectious on different cell types. Of interest, E proteins on
individual virions in conformations that may no longer contribute
functionally to fusion may also stably expose a different array of
epitopes.
Our data suggest that the circumstances of antibody-virion
interactions may significantly impact the fate of the virion immune
complex. Standard in vitro neutralization assays for flaviviruses generally
include a short pre-incubation (,1 hr) of antibody and virus prior to
infection of target cells; this incubation presumably allows the binding
reaction between antibody and cognate epitope to reach steady-state.
However, depending on the extent to which a virion is structurally
dynamic (which controls the rate at which epitopes may become
transiently accessible), the target cell type, and the volume of infection
in vitro, this presumption may be inaccurate. Because increases in the
neutralization activity of DENV-reactive antibodies that bind
dynamically exposed epitopes occur rapidly (within two hours)
(Figure 7), the interaction of DENV with antibodies may never truly
reach steady-state. From this perspective, the length of time antibody is
incubated with DENV is a variable that cannot be ignored. While
antibody-mediated neutralization activity measured in vitro using
standard plaque reduction neutralization tests (PRNT) generally
correlates with protection in vivo [39,53,54,60,61,62], this is an
imperfect relationship. Antibodies with limited neutralization activity
have been shown to protect in animal models of flavivirus infection
[39,54,62]. While this may reflect the direct contributions of effector
functions of antibodies in vivo,i ti sa l s op o s s i b l et h a te x i s t i n ga s s a y so ft h e
functional properties of antibodies have limitations. Considering the
contribution of the structural dynamics of the virion when designing
neutralization studies merits a systematic evaluation.
The impact of the dynamic exposure of viral epitopes in vivo
remains uncertain. Virtually nothing is known about the relevant
concentrations and volumes that govern antibody-virion interac-
tions in the tissues where many of the key events in the
pathogenesis of these viruses occur. Kinetic changes in neutral-
ization occur gradually over time as dynamic motion provides new
opportunities for engagement of virions with a stoichiometry
sufficient for neutralization (Figure S3). Thus the rate of virus
entry in vivo is also an important, yet unknown, parameter that
defines the extent to which this phenomenon will contribute to
protection of the host. Of interest, the kinetics of WNV binding to
target cells in vitro occurred rather slowly (with maximal binding
requiring ,3 hours) even in the presence of the high affinity
attachment factor DC-SIGNR (Figure S6). As DENV appears to
be extremely dynamic, with kinetic effects on neutralization
observed almost immediately, the impact of viral breathing on
neutralization in vivo cannot be discounted. Because the kinetics of
neutralization are increased by an elevated temperature, it is
interesting to speculate that certain classes of antibodies, such as
those recognizing the fusion loop epitope commonly observed in
infected individuals, may function better than previously antici-
pated in the context of the febrile response. Resolving this question
awaits the development of approaches to quantitatively and
directly measure antibody-mediated neutralization in vivo.
Neither proteins, nor intact virions, are static structures. Our
findings are consistent with a model in which the dynamic motion of
flaviviruses provides an opportunity for antibodies to engage virions
at otherwise inaccessible epitopes to reach a stoichiometry sufficient
for neutralization. Given time, all of the E protein-reactive antibodies
investigated were able to block virus infection, even those described
Kinetic Aspects of WNV Neutralization
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results add to the complexity of our understanding of the functional
properties of antibodies and suggest new avenues of investigation and




Cell lines were maintained at 37uC in the presence of 7% CO2.
HEK-293T cells were grown in complete Dulbecco’s modified Eagle
medium (DMEM) containing Glutamax (Invitrogen, Carlsbad, CA)
and supplemented with 10% fetal bovine serum (FBS; (HyClone,
Logan, UT)) and 100 U/ml penicillin-streptomycin (PS; (Invitrogen,
Carlsbad, CA)). K562 and Raji cell lines were maintained in RPMI-
1640 medium containing Glutamax (Invitrogen, Carlsbad, CA) and
supplemented with 10% FBS and 100 U/ml PS.
WNV and DENV immune sera
Neutralization studies were performed using sera obtained from
recipients of a candidate WNV vaccine. Sera from five participants
of a Phase I double-blinded, placebo-controlled study designed to
evaluate the safety and immunogenicity of a single dose of live
attenuated WNV/DENV-4 vaccine were obtained and charac-
terized previously [21]. The clinical study was conducted at the
Center for Immunization at the Johns Hopkins Bloomberg School
of Public Health under an investigational new drug application
reviewed by the United States Food and Drug Administration.
Production of WNV and DENV RVPs
Reporter virus particles (RVPs) are pseudo-infectious virions
produced by genetic complementation of a WNV sub-genomic
replicon with the structural genes in trans. Flavivirus replicons do
not encode intact genes for the three structural proteins of the
virus, thus RVPs that encapsidate these sub-genomic RNAs are
capable of only a single round of infection. WNV and DENV
RVPs have been used extensively to characterize the functional
properties of anti-flavivirus antibodies [21,38,39,42,63,64].
RVPs were produced by transfection of HEK-293T cells with
DNA plasmids encoding the structural genes and a sub-genomic
WNV replicon as described previously [38,65]. Standard
preparations of WNV RVPs were produced using plasmids
encoding a GFP-expressing replicon, WNV C-prM-E, and
pcDNA3.1 with a 1:3:0.5 ratio by mass. Because standard
preparations of WNV RVPs retain detectable amounts of
uncleaved prM, homogeneous populations of mature WNV
RVPs were produced using the plasmids above except that a
plasmid encoding human furin was used in place of pcDNA3.1 to
promote efficient cleavage of prM [21]. Over-expression of furin
in this context has been shown to reduce the amount of
uncleaved prM protein in populations of RVPs to levels that are
no longer detectable by Western blot [21,66]. Standard RVPs
composed of the structural genes of the DENV Western Pacific
strain (serotype I: genotype IV) were produced as described above
by substituting a plasmid encoding DENV structural genes in
place of the WNV construct [49]. All transfections were
performed using Lipofectamine LTX (Invitrogen, Carlsbad,
CA) in accordance with the manufacturer’s instructions. RVPs
were harvested at 48 h post-transfection, filtered through a
0.22 mM filter, and frozen in aliquots at 280uC.
Determining the infectious titer of RVPs
Because the relationship between infected cells and virus dose is
typically not linear for flaviviruses, the titers of all RVP stocks were
measured by serial dilution. Serial two-fold dilutions of RVP-
containing supernatants were used to infect Raji cells that express
the attachment factor DC-SIGNR. Infection was measured 48 h
post-infection by flow cytometry. Only data obtained from the
linear portion of the resulting virus dose-response curves was used
for analysis.
Measurements of kinetic aspects of antibody-mediated
neutralization and ADE
Single concentration studies. WNV RVP stocks were
diluted in the presence or absence of 10 ng/ml MAb E16 or
200 ng/ml MAb 3H5 in a total volume of ,7 ml and pre-
incubated for one hour at room temperature to allow the binding
reaction to reach equilibrium. The virus mixtures were further
incubated at 37uC for up to four days, during which 450 ml
samples were removed at indicated times and frozen for analysis.
Two-fold dilutions of RVPs from each sample were used to infect
Raji-DC-SIGNR cells at 37uC (200 ml total volume). Infectivity
was determined 48 h post-infection by flow cytometry. Using
values corresponding to the linear portion of the curve, infectivity
was normalized to levels obtained prior to incubation at 37uC (but
after the initial room temperature incubation) and fitted to a
single-phase exponential decay to obtain the half-life (GraphPad
Prism; GraphPad Software, La Jolla, CA).
Dose-response studies. To assess the kinetic aspects of
neutralization over a range of antibody concentrations, WNV RVP
stocks were diluted into the linear range of infectivity and incubated
with serial dilutions of the indicated MAbs, Fab fragments, or
polyclonal sera. To ensure our experiments were performed under
conditions of antibody excess, antibody dose-response studies were
performed using multiple dilutions of RVPs. These studies confirmed
that the concentration of RVPs does not affect neutralization potency
(EC50), as predicted by the assumptions of the law of mass action and
the percentage law [65,67]. Antibody-virus complexes were initially
incubated for one hour at room temperature to allow the binding
reaction to reach equilibrium, and then further incubated at 33uC,
37uC, or 40uC for incremental lengths of time, at which point the
infectivity of virus-antibody complexes was determined by infecting
Raji-DC-SIGNR target cells. Infections were carried out at 37uC
(300 mltotalvolume)andinfectivitywasmonitoredbyflowcytometry
48 h post-infection. In addition to the half-life data at each
concentration of MAb or dilution of sera (calculated as described
above), dose-response curves at each time point were analyzed by
non-linear regression (variable slope) to predict the EC50 value using
G r a p h P a dP r i s m( G r a p h P a dS o f t w a r e ,L aJ o l l a ,C A ) .I nas u b s e to f
experiments, K562 cells that express the activating human FccIIb-
receptor CD32a were used instead of Raji-DC-SIGNR cells in order
to assess kinetic changes in ADE profiles. Neutralization studies with
DENV-1 RVPs were performed analogous to WNV-Raji-DC-
SIGNR infections, except the initial one hour incubation allowing
for equilibrium was performed at 37uC instead of at room
temperature.
Quantitative real-time PCR
The genomic RNA content of RVP populations was measured
using a modification of a previously described protocol [68].
Briefly, RVP containing supernatants were treated with 100 U
recombinant DNase I, followed by RNA isolation using the
QiaAmp Viral RNA Mini kit per the manufacturer’s instructions
(Qiagen, Valencia, CA). Amplification of viral genomic RNA was
accomplished using the Superscript III One-Step RT-PCR system
(Invitrogen, Carlsbad, CA) and primers specific for the 39
untranslated region of the WNV lineage II replicon [69].
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Standard preparations of WNV RVPs were incubated with
Raji-DC-SIGNR cells at 37uC in the absence or presence of the
MAb E16 for incremental lengths of time to allow virus-cell
binding to occur. Target cells were incubated in the presence of
20 mM NH4Cl to prevent virus fusion and genomic RNA
replication. At the indicated times, cells were washed extensively
with media and lysed. Total RNA was isolated using the
QIAshredder and RNeasy Mini kits in accordance with the
manufacturer’s instructions (Qiagen, Valencia, CA). The relative
amount of bound WNV RNA was enumerated by quantitative
real-time PCR using a DNA molecular clone plasmid as a
standard [49,68]. The resulting kinetic data was fit to a one-phase
association model using GraphPad Prism (GraphPad Software, La
Jolla, CA).
Supporting Information
Figure S1 Virus-antibody steady-state binding. Standard
preparations of WNV or DENV-1 RVPs were incubated with
serial four-fold dilutions of the indicated MAbs for the specified
time periods prior to the addition of Raji-DC-SIGNR target cells.
Infectivity was carried out at 37uC and monitored by flow
cytometry at 48 h post-infection. Dose-response curves from
representative experiments are expressed relative to the level of
infectivity in the absence of antibody for each time point. (A)N o
significant difference in the EC50 of MAb E16 was observed
whether cells were added immediately to RVP-antibody complex-
es (0 min) or after 15, 30, 45, or 60 minutes of incubation at room
temperature (n=3; p=.83). Similar experiments were performed
with MAb E60, which binds the DII-fusion loop with high affinity,
mediates neutralization primarily by blocking attachment to target
cells [28], and is cross-reactive for DENV. No differences in the
E60 neutralization dose-response profiles were observed whether
cells were added to WNV (B) or DENV-1 (C) RVP-antibody
complexes immediately or after 60 minutes of incubation at room
temperature or 37uC. Additionally, similar results were obtained
using the WNV-specific MAb E24 and WT WNV RVPs (D)o ra
variant incorporating a T330I mutation in the DIII-lateral ridge
epitope recognized by this antibody (E). E24 binds with
significantly reduced affinity to T330I WNV (too low to be
measured by ELISA) and has been shown previously to poorly
neutralize this variant [38]. No differences were observed whether
cells were added to virus-antibody complexes immediately or after
30 or 60 minutes of incubation at room temperature. Overall,
these results demonstrate the fast kinetics of antibody binding, and
indicate that incubation for one hour (either at RT or 37uC) is
sufficient for steady-state binding of antibody to WNV. Error bars
display the standard error of duplicate infections. Data is
representative of three (A), two (B and C), and one (D and E)
independent experiment(s). RT=room temperature.
(TIF)
Figure S2 The reduction in WNV infectivity in the
presence of antibody cannot be explained by adherence
of antibody-virus complexes to tissue culture plastic, the
activation of complement, or the activity of proteases in
the culture media. (A) To rule out the impact of antibody-virus
complexes adhering to tissue culture plastic and thereby
disappearing from solution, we used quantitative RT-PCR to
measure the amount of WNV RNA in samples collected
immediately after the room temperature incubation required to
achieve steady-state binding as compared to samples collected
after lengthy incubation at 37uC( .72 h), either in the absence or
presence of 10 ng/ml E16 (purple and blue bars, respectively).
The data is presented as the ratio of WNV genomes present prior
to incubation at 37uC versus after incubation. The error bars
represent the standard error of five independent experiments
(p=.32). (B and C) WNV RVPs were incubated in the absence or
presence of 10 ng/ml E16 and, in some cases, a protease inhibitor
(PI) cocktail (0.16, Sigma-Aldrich) for one hour at room
temperature to allow binding to reach equilibrium, after which
the RVP-antibody complexes were incubated at 37uC. At
incremental times, the infectivity of RVPs removed from 37uC
incubation was determined following infection of Raji-DC-SIGNR
cells. Infectivity was monitored by flow cytometry at 48 h post-
infection and normalized to levels obtained prior to incubation at
37uC (but after equilibrium was reached). Normalized infectivity
data was fitted to a single-phase exponential decay to obtain the
half-life. The fold-decrease in RVP half-life was calculated by
comparison to the half-life of RVPs incubated alone (the intrinsic
decay rate). (B) To rule out a role for complement activation, we
utilized an engineered E16 variant, chE16 N297Q, that cannot
bind the complement component C1q [38,42]. WNV RVPs were
incubated in the presence of 10 ng/ml chE16 (control MAb with
intact C1q binding ability) or 10 ng/ml of the chE16 N297Q
MAb (purple and blue bars, respectively). The error bars
represents the standard error of five independent experiments
(p=.17). (C) To rule out the impact of contaminating proteases in
solution, WNV RVPs were incubated in the presence of PI
cocktail alone, 10 ng/ml E16 alone, or both (purple, blue, and
green bars, respectively). The error bars represent the standard
error of two independent experiments (p=.74, blue vs. green
bars).
(TIF)
Figure S3 The effects of epitope accessibility on kinetic
increases in neutralization. WNV neutralization is a multiple-
hit phenomenon achieved when an individual virion is bound by
antibody with a stoichiometry that exceeds a required threshold; our
estimate of this threshold is 30 antibodies per virion (red dashed line)
(reviewed by [29]). From this perspective, neutralization of flavivirus
virions is governed by antibody affinity/avidity and epitope
accessibility (the number of epitopes available for antibody binding).
Most of the known flavivirus epitopes recognized by antibodies are
poorly accessible on the mature virion due to steric constraints arising
from the complex pseudo-icosahedral arrangement of E proteins
[38,39,40,52]. Changes in epitope accessibility that occur during
virion maturation have been shown to significantly impact antibody-
mediated neutralization of WNV [21,52]. Epitope accessibility may
also vary as a function of the dynamic motion, or ‘‘breathing’’, of
flavivirus E proteins on the mature virus particle. An increase in
epitope accessibility via dynamic motion results in time-dependent
increases in neutralization. As the number of accessible epitopes on
the individual virion increases, the fraction of them that must be
bound in order to exceed the stoichiometric threshold (percent
occupancy) is reduced. For example, MAb E16 recognizes a relatively
accessible epitope on the lateral ridge of DIII (shown as red spheres,
adapted from [38]); 120 of 180 E proteins can be bound on the
‘‘average’’ state of the mature WNV virion [27,28]. From this
perspective, neutralization by E16 requires occupancy of 25% of the
accessible epitopes on the virion. Increases in accessibility of the
remaining 60 epitopes through dynamic motion of the E proteins
result in a modest increase in neutralization potency; should all
epitopes on the virion become accessible, neutralization will occur at
an occupancy of 17% of the E proteins. By comparison, MAb E22
binds an epitope that is inaccessible on the mature virion (shown as
red spheres, adapted from [38]). Most mature virions cannot be
neutralized by E22 because they do not display a sufficient number of
epitopes to allow for neutralization even when in the presence of
Kinetic Aspects of WNV Neutralization
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of the E22 epitope reduces the proportion of virions refractory to
neutralization becausethe number of accessibleepitopes on the virion
becomes larger than the requirements of the neutralization threshold.
Consequently, the occupancy requirements for neutralization are
reduced, allowing neutralization of virions at lower concentrations of
antibody. Because the number of epitopes available for binding by
E16 on the mature virion is significantly greater than the cryptic
determinants bound by E22, changes in neutralization occur more
rapidly. In contrast, virions that display a very small number of
epitopes relative to the stoichiometric threshold (such as for E22) may
become sensitive to neutralization relatively slowly because the
number of epitopes that must become accessible and s[ly bound by
antibody is relatively large.
(TIF)
Figure S4 Differences in the rate of kinetic changes in
neutralization for WNV and DENV-1 using a cross-
reactive MAb. Nine serial four-fold dilutions of the cross-reactive
DII-fusion loop-specific MAb E60 were incubated with WNV and
DENV-1 RVPs for one hour at 37uC to allow binding to reach
equilibrium. RVP-antibody complexes were then incubated at
37uCo r4 0 uC for the indicated lengths of time before infecting
Raji-DC-SIGNR cells. Infectivity was monitored by flow cytom-
etry at 48 h post-infection. The reference curve represents RVP-
antibody complexes added to Raji-DC-SIGNR cells immediately
after the one hour incubation required to achieve steady-state
binding. Dose-response curves are expressed relative to the
infectivity of RVPs in the absence of antibody at each time point.
Error bars display the standard error of duplicate infections.
Results are representative of two independent experiments.
(TIF)
Figure S5 Limits of the kinetic changes in neutraliza-
tion and ADE. Nine serial four-fold dilutions of MAb E16 were
incubated with WNV RVPs for one hour at room temperature to
allow binding to reach equilibrium. RVP-antibody complexes
were then incubated at 37uC for incremental lengths of time
before infecting Raji-DC-SIGNR (A) or K562 (B) cells. Infectivity
was monitored by flow cytometry at 48 h post-infection. The
reference curve represents RVP-antibody complexes added to cells
immediately after the room temperature incubation. Dose-
response curves from representative experiments are expressed
relative to the infectivity in the absence of antibody at each
individual time point (A) or, in the case of ADE, the maximum
infectivity at each time point (B). Error bars display the standard
error of duplicate infections. Data is representative of four (A) and
three (B) independent experiments.
(TIF)
Figure S6 WNV attachment to cells is relatively slow.
WNV RVPs were bound to Raji-DC-SIGNR cells for up to
,400 minutes at 37uC in the absence (purple) or presence of sub-
neutralizing (green) or neutralizing (blue) concentrations of the
MAb E16. Virus binding was measured by tracking the presence
of the viral genome using quantitative real-time PCR. Viruses
were bound to cells for the indicated times and washed extensively
before RNA analysis. Cells were treated with ammonium chloride
to block viral fusion in the endosome and prevent the synthesis of
viral RNA following infection. (A) The amount of WNV RNA
bound is expressed as a function of the maximum binding in the
absence of antibody. Error bars represent the standard error of
duplicate measurements. (B) The resulting kinetic data was fit to a
one-phase association model to obtain the binding rate constant.
The means of five independent experiments are shown; error bars
represent the standard errors.
(TIF)
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